Graybug Vision is developing five therapeutic candidates for the treatment of chronic vision-threatening ophthalmic diseases.

The lead candidate, GB-102, is a clinical-stage depot formulation of sunitinib malate aimed at reducing intravitreal injections in patients with wet AMD currently managed with anti-vascular endothelial growth factor agents (anti-VEGF) such as aflibercept (Eylea®), bevacizumab (Avastin®), or ranibizumab (Lucentis®). Other compounds under development are for the treatment of elevated IOP in patients with open-angle glaucoma or ocular hypertension.